<DOC>
<DOCNO>EP-0658198</DOCNO> 
<TEXT>
<INVENTION-TITLE>
MULTICISTRONIC EXPRESSION UNITS AND THEIR USE
</INVENTION-TITLE>
<CLASSIFICATIONS>C12Q102	C12N1567	C12N1509	C07H2100	C12N1512	A61K3822	C12Q102	A61P4300	C12N1509	C12N510	C12N1585	A61K3800	B29C4776	C07H2104	A61K3800	C12P2102	C12N1512	C12N1585	C07K1449	C12N1567	B29C4776	C07K14435	A61K3822	C12P2102	C12N510	A61P4300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C12Q	C12N	C12N	C07H	C12N	A61K	C12Q	A61P	C12N	C12N	C12N	A61K	B29C	C07H	A61K	C12P	C12N	C12N	C07K	C12N	B29C	C07K	A61K	C12P	C12N	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C12Q1	C12N15	C12N15	C07H21	C12N15	A61K38	C12Q1	A61P43	C12N15	C12N5	C12N15	A61K38	B29C47	C07H21	A61K38	C12P21	C12N15	C12N15	C07K14	C12N15	B29C47	C07K14	A61K38	C12P21	C12N5	A61P43	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Multicistronic expression units allow the equimolar expression of the genes located in the corresponding cistrons. These expression units are particularly suitable for the recombinant production of proteins composed of two or more polypeptide subunits.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Multicistronic expression unit for the equimolar
expression of polypeptides or subunits thereof in

mammalian cells as host cells, characterized by the
general formula


p - 5'UTR - C
1
 - (IRES - Y - C
2
)
n
 - 3'UTR - polyA,

in which

"p" is a transcriptional promoter,
"5'UTR" is an untranslated nucleotide sequence,
n is 1, 2 or 3,
"C
1
" and "C
2
" are cistrons which in each case
contain a gene encoding a polypeptide or its

subunit, in which case, if n is 2 or 3, the
sequences C
2
 of the successive groups (IRES-Y-C
2
)
may be identical to or different from each other

and, furthermore, C
1
 and C
2
 may be identical or
different,
"IRES" is a nucleotide sequence of viral, cellular
or synthetic origin, which at the stage of

translation is responsible for internal initiation,
"Y" is a nucleotide sequence which, in synergy
with IRES, ensures expression of the gene(
s)
contained in C
2
 in such a manner that the gene
products of C
1
 and C
2
 are expressed in equimolar 
quantities,
"3'UTR" is an untranslated nucleotide sequence,

and
"polyA" is a polyadenylation signal.
Expression unit according to Claim 1, characterized
in that the IRES is the 5'UTR of polio virus type

1, 2 or 3, of encephalomyocarditis virus (EMV), of
"Theiler's murine encephalomyelitis virus" (TMEV), of

"foot-and- mouth disease virus" (FMDV), of "bovine
enterovirus" (BEV), of "coxsackie B virus" (CBV), or of

"human rhinovirus" (HRV), or the "human immunoglobulin
heavy chain binding protein" (BIP) S'UTR, the Drosophila

antennapediae 5'UTR or the Drosophila ultrabithorax
5'UTR, or genetic hybrids or fragments from the above-listed

sequences.
Expression unit according to Claim 1 or 2,
characterized in that the IRES is the nucleotide sequence

according to SEQ ID NO: 5.
Expression unit according to Claims 1 to 3,
characterized in that "Y" is the β-globin sequence from

Xenopus laevis, the alfalfa mosaic virus RNA4 5'UTR,
ferritin 5'UTR (animal), tobacco mosaic virus S'UTR

(omega), or their leader mutants, turnip yellow mosaic
virus (TYMV) S'UTR, brome mosaic virus (BMV) RNA3 5'UTR,

Rous sarcoma virus (RSV) 5'UTR, adenovirus tripartite
leader (L1-3) and variants thereof, Xenopus borealis

5'UTR β-globin or Xenopus tropicalis 5'UTR β-globin
sequence.
Expression unit according to Claims 1 to 4,
characterized in that "Y" is the β-globin sequence from

Xenopus laevis according to SEQ ID NO: 6, or a fragment
or a variant thereof.
Expression unit according to Claims 1 to 4,
characterized in that the IRES is the polio virus type 1

UTR according to SEQ ID NO: 5 and "Y" is the β-globin 
sequence from Xenopus laevis according to SEQ ID NO: 4.
Expression unit according to Claims 1 to 6,
characterized in that C
1
 and C
2
 in each case contain genes
which encode polypeptide subunits of single or heteromeric

proteins.
Expression unit according to Claims 1 to 7,
characterized in that C
1
 and C
2
 in each case contain genes
which encode the different subunits of factor VIII,

creatine kinase, haemoglobin, immunoglobulins, histocompatibility
antigens, scatter factor (HGF-SF), members of

the transforming growth factor type β family, of bone
morphogenic protein (BMP), members of the integrin

family, or PDGF, or their natural or synthetic variants
and derivatives.
Expression unit according to Claim 6, characterized
in that "n" is 1 and C
1
 and C
2
 alternatively
contain a gene encoding the A or B chain of PDGF, or a

biologically active analogue or a fragment thereof, both
genes being represented simultaneously in the expression

unit.
Expression unit according to Claim 9, characterized
in that C
1
 or C
2
 contains the PDGF-A
K
 (SEQ ID NO:
1) or the PDGF-A
L
 precursor sequence.
Expression unit according to Claim 9 or 10,
characterized in that C
1
 or C
2
 contains the complete PDGF-B
precursor sequence (SEQ ID NO: 3), the 
v-sis
 gene from
simian sarcoma virus, or variants of these sequences.
Expression unit according to Claims 9 to 11,
characterized in that C
1
 or C
2
 contains a gene fragment
which encodes a PDGF-B precursor molecule which is

truncated by replacing the arginine-encoding codon in
amino acid position 191 by a translation stop codon (SEQ

ID NO: 24).
Expression unit according to Claim 9, characterized
in that C
1
 and C
2
 alternatively contain the PDGF-A
K

sequence (SEQ ID NO: 1) or the truncated PDGF-B190
precursor sequence (SEQ ID NO: 24), and both genes are

represented simultaneously in the expression unit.
Expression unit according to Claims 1 to 6, 
characterized in that "n" is 1 and C
1
 and C
2
 contain
reporter genes which are different from each other.
Expression unit according to Claim 14, characterized
in that the reporter genes encode luciferase and

secretory alkaline phosphatase.
Recombinant DNA vector which contains an expression
unit according to Claims 1 to 15 inserted in an

operative manner.
Host cell which is a mammalian cell transformed
with a vector according to Claim 16.
Host cell according to Claim 17, characterized in
that it is a CHO or BHK cell.
Host cell, characterized in that it is a mammalian
cell which is transformed with a vector which

contains the expression unit according to Claims 9 to 13
inserted in an operative manner.
Host cell according to Claim 19, characterized in
that it is a CHO or BHK cell.
Host cell according to Claim 20, characterized in
that it is a PDGF-AB-producing BHK cell which is derived

from one of the clones 92-22-6, corresponding to DSM ACC
2048, or 92-22-7, corresponding to DSM ACC 2049.
Process for preparing proteins consisting of
equimolar proportions of polypeptide subunits, characterized

in that host cells according to Claims 17 to 21
are cultivated in a suitable medium and the resulting

protein is separated off from the cells and the medium.
Process according to Claim 22 for preparing
heteromeric proteins.
Process according to Claim 22 or 23, characterized
in that the protein is factor VIII, creatine

kinase, haemoglobin, an immunoglobulin, a
histocompatibility antigen, scatter factor (HGF-SF), a

member of the transforming growth factor type β family,
bone morphogenic protein (BMP), a member of the integrin

family, or PDGF, or a natural or synthetic variant or a
derivative thereof.
Process for preparing heteromeric rPDGF-AB,
characterized in that host cells according to Claims 19 

to 21 are cultivated in a suitable medium and the resulting
rPDGF-AB is separated off from the cells and the

medium.
Process for preparing an rPDGF-AB-containing
pharmaceutical and/or cosmetic preparation, characterized

in that the process according to Claims 22 to 25 is
carried out and the rPDGF-AB which is separated off is

formulated in a further step together with pharmaceutically
and/or cosmetically tolerated auxiliaries and

excipients.
Process according to Claim 26, characterized in
that the pharmaceutical and/or cosmetic preparation is an

ointment, a spray, gel, wound bandage, a plaster or a
wound dressing.
Host cell, characterized in that it is a mammalian
cell which is transformed with a vector which

contains the expression unit according to Claims 14 or 15
inserted in an operative manner.
Host cell according to Claim 28, characterized in
that it is derived from the clone 91-46-9, corresponding

to DSM ACC 2046.
Process for detecting translation-influencing "Y"
sequences which, in synergy with the IRES, bring about

the equimolar expression of the gene products of C
1
 and C
2

in expression units according to Claims 1 to 15, characterized
in that


(a) the sequences to be investigated as Y are introduced
into expression units according to Claim 1, 14 or

15,
(b) vectors are constructed which contain the respective
expression unit inserted in an operative manner,
(c) mammalian cells, as host cells, are transformed with
the vectors from step (b) and cultivated in a

suitable medium, and
(d) the expression products of C
1
 and C
2
 are quantified
in the medium or following separation from the cells

and/or the medium.
Process according to Claim 30, characterized in
that CHO or BHK cells are used as host cells in step (c). 
Process according to Claim 30, characterized in
that host cells according to Claim 28 are used in step

(c).
Process according to Claims 30 to 32, characterized
in that the IRES is a sequence according to SEQ

ID NO: 5.
Process for detecting translation-initiating IRES
sequences which, in synergy with "Y", bring about the

equimolar expression of the gene products of C
1
 and C
2
 in
expression units according to Claim 1 to 15, characterized

in that

(a) the sequences to be investigated as the IRES are
introduced into expression units according to Claim

1, 14 or 15,
(b) vectors are constructed which contain the respective
expression unit inserted in an operative manner,
(c) mammalian cells, as host cells, are transformed with
the vectors from step (b) and cultivated in a suitable

medium, and
(d) the expression products of C
1
 and C
2
 are quantified
in the medium or following separation from the cells

and/or the medium.
Process according to Claim 34, characterized in
that CHO or BHK cells are used as host cells in step (c).
Process according to Claim 34, characterized in
that host cells according to Claim 28 are used in step

(c).
Process according to Claims 34 to 36, characterized
in that "Y" is a sequence according to SEQ ID NO:

6.
</CLAIMS>
</TEXT>
</DOC>
